DARE Relative Valuation
DARE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DARE is overvalued; if below, it's undervalued.
Historical Valuation
Dare Bioscience Inc (DARE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.36 is considered Undervalued compared with the five-year average of -3.02. The fair price of Dare Bioscience Inc (DARE) is between 4.60 to 37.14 according to relative valuation methord. Compared to the current price of 2.04 USD , Dare Bioscience Inc is Undervalued By 55.65%.
Relative Value
Fair Zone
4.60-37.14
Current Price：2.04
55.65%
Undervalued
-2.84
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Dare Bioscience Inc. (DARE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.32
EV/EBIT
Dare Bioscience Inc. (DARE) has a current EV/EBIT of -0.32. The 5-year average EV/EBIT is -1.56. The thresholds are as follows: Strongly Undervalued below -2.85, Undervalued between -2.85 and -2.21, Fairly Valued between -0.92 and -2.21, Overvalued between -0.92 and -0.28, and Strongly Overvalued above -0.28. The current Forward EV/EBIT of -0.32 falls within the Overvalued range.
1.36
PS
Dare Bioscience Inc. (DARE) has a current PS of 1.36. The 5-year average PS is 14.97. The thresholds are as follows: Strongly Undervalued below -18.09, Undervalued between -18.09 and -1.56, Fairly Valued between 31.50 and -1.56, Overvalued between 31.50 and 48.03, and Strongly Overvalued above 48.03. The current Forward PS of 1.36 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Dare Bioscience Inc. (DARE) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.10. The thresholds are as follows: Strongly Undervalued below -3.50, Undervalued between -3.50 and -1.80, Fairly Valued between 1.60 and -1.80, Overvalued between 1.60 and 3.30, and Strongly Overvalued above 3.30. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Dare Bioscience Inc. (DARE) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.06. The thresholds are as follows: Strongly Undervalued below -3.69, Undervalued between -3.69 and -1.87, Fairly Valued between 1.75 and -1.87, Overvalued between 1.75 and 3.56, and Strongly Overvalued above 3.56. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Dare Bioscience Inc (DARE) has a current Price-to-Book (P/B) ratio of 9.50. Compared to its 3-year average P/B ratio of -2.64 , the current P/B ratio is approximately -460.18% higher. Relative to its 5-year average P/B ratio of -2.41, the current P/B ratio is about -494.41% higher. Dare Bioscience Inc (DARE) has a Forward Free Cash Flow (FCF) yield of approximately -24.57%. Compared to its 3-year average FCF yield of -42.21%, the current FCF yield is approximately -41.81% lower. Relative to its 5-year average FCF yield of -37.37% , the current FCF yield is about -34.26% lower.
9.50
P/B
Median3y
-2.64
Median5y
-2.41
-24.57
FCF Yield
Median3y
-42.21
Median5y
-37.37
Competitors Valuation Multiple
The average P/S ratio for DARE's competitors is 1.08, providing a benchmark for relative valuation. Dare Bioscience Inc Corp (DARE) exhibits a P/S ratio of 1.36, which is 26.21% above the industry average. Given its robust revenue growth of -94.57%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of DARE decreased by 39.38% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -11.28K to -157.51K.
The secondary factor is the Revenue Growth, contributed -94.57%to the performance.
Overall, the performance of DARE in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
NXPL
NextPlat Corp
0.6171USD
-0.80%
BCAB
Bioatla Inc
0.3977USD
-6.13%
WKHS
Workhorse Group Inc
5.59USD
4.29%
ZOOZ
Zooz Strategy Ltd
0.48315USD
-6.94%
FOXX
Foxx Development Holdings Inc
4.57USD
7.53%
COCH
Envoy Medical Inc
0.7USD
0.86%
JOB
GEE Group Inc
0.2USD
-0.50%
HVT.A
Haverty Furniture Companies Inc
24.72USD
6.83%
HUIZ
Huize Holding Ltd
2.23USD
-1.33%
Frequently Asked Questions
Is Dare Bioscience Inc (DARE) currently overvalued or undervalued?
Dare Bioscience Inc (DARE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.36 is considered Undervalued compared with the five-year average of -3.02. The fair price of Dare Bioscience Inc (DARE) is between 4.60 to 37.14 according to relative valuation methord. Compared to the current price of 2.04 USD , Dare Bioscience Inc is Undervalued By 55.65% .
What is Dare Bioscience Inc (DARE) fair value?
DARE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Dare Bioscience Inc (DARE) is between 4.60 to 37.14 according to relative valuation methord.
How does DARE's valuation metrics compare to the industry average?
The average P/S ratio for DARE's competitors is 1.08, providing a benchmark for relative valuation. Dare Bioscience Inc Corp (DARE) exhibits a P/S ratio of 1.36, which is 26.21% above the industry average. Given its robust revenue growth of -94.57%, this premium appears unsustainable.
What is the current P/B ratio for Dare Bioscience Inc (DARE) as of Jan 08 2026?
As of Jan 08 2026, Dare Bioscience Inc (DARE) has a P/B ratio of 9.50. This indicates that the market values DARE at 9.50 times its book value.
What is the current FCF Yield for Dare Bioscience Inc (DARE) as of Jan 08 2026?
As of Jan 08 2026, Dare Bioscience Inc (DARE) has a FCF Yield of -24.57%. This means that for every dollar of Dare Bioscience Inc’s market capitalization, the company generates -24.57 cents in free cash flow.
What is the current Forward P/E ratio for Dare Bioscience Inc (DARE) as of Jan 08 2026?
As of Jan 08 2026, Dare Bioscience Inc (DARE) has a Forward P/E ratio of -2.84. This means the market is willing to pay $-2.84 for every dollar of Dare Bioscience Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Dare Bioscience Inc (DARE) as of Jan 08 2026?
As of Jan 08 2026, Dare Bioscience Inc (DARE) has a Forward P/S ratio of 1.36. This means the market is valuing DARE at $1.36 for every dollar of expected revenue over the next 12 months.